Literature DB >> 31996009

Noninvasive prenatal diagnosis of hemophilia A by a haplotype-based approach using cell-free fetal DNA.

Chao Chen1,2, Jun Sun1, Yun Yang2, Lu Jiang1, Fengyu Guo1, Yaping Zhu1, Dan Li3, Renhua Wu1, Rong Lu3, Mei Zhao4, Fang Chen5, Peixiang Ni1, Zhihui He3, Zhiyu Peng5.   

Abstract

Aim: We aimed to demonstrate noninvasive prenatal diagnosis (NIPD) of hemophilia A (HA) using a haplotype-based approach.
Methods: Two families at risk for HA were recruited for this study. First, maternal haplotypes associated with pathogenic variants were constructed using the genotypes of the mothers and probands. Then, fetal haplotypes were deduced using a maternal haplotype-assisted hidden Markov model. Finally, the NIPD results were further confirmed by invasive prenatal diagnosis.
Results: Two fetal genotypes were successfully inferred, with one normal fetus and one carrier fetus. The NIPD results were confirmed by invasive prenatal diagnosis, with a 100% consistency rate.
Conclusion: Our test has been shown to be accurate and reliable. With further validation in a large patient cohort, this haplotype-based approach could be feasible for the NIPD of HA and other X-linked single-gene disorders.

Entities:  

Keywords:  factor VIII; haplotype; hemophilia A; noninvasive prenatal diagnosis; targeted sequencing

Mesh:

Substances:

Year:  2020        PMID: 31996009     DOI: 10.2144/btn-2019-0113

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  2 in total

1.  Development of a Specific Monoclonal Antibody to Detect Male Cells Expressing the RPS4Y1 Protein.

Authors:  Silvia Spena; Chiara Cordiglieri; Isabella Garagiola; Flora Peyvandi
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

Review 2.  Congenital hemophilia A with low activity of factor XII: a case report and literature review.

Authors:  Baoyu Lei; Chuang Liang; Haiyan Feng
Journal:  Ital J Pediatr       Date:  2021-10-11       Impact factor: 2.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.